EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Allele-specific gene-editing approach for vision loss restoration in RHO-associated retinitis pigmentosa

Xiaozhen Liu iD, Jing Qiao, Ruixuan Jia, Fan Zhang, Xiang Meng, Yang Li, Liping Yang iD

eLife · 2023

DOI: 10.7554/elife.84065 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, 2023. Verfasst von Xiaozhen Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Third Hospital, Peking University, Beijing, China. Hauptthemen laut MEDLINE: Rhodopsin, Retinitis Pigmentosa. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, the Beijing Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutant RHO is the most frequent genetic cause of autosomal dominant retinitis pigmentosa (adRP). Here, we developed an allele-specific gene-editing therapeutic drug to selectively target the human T17M RHO mutant allele while leaving the wild-type RHO allele intact for the first time. We identified a Staphylococcus aureus Cas9 (SaCas9) guide RNA that was highly active and specific to the human T17M RHO allele. In vitro experiments using HEK293T cells and patient-specific induced pluripotent stem cells (iPSCs) demonstrated active nuclease activity and high specificity. Subretinal delivery of a single adeno-associated virus serotype 2/8 packaging SaCas9 and single guide RNA (sgRNA) to the retinas of the RHO humanized mice showed that this therapeutic drug targeted the mutant allele selectively, thereby downregulating the mutant RHO mRNA expression. Administration of this therapeutic drug resulted in a long-term (up to 11 months after treatment) improvement of retinal function and preservation of photoreceptors in the heterozygous mutant humanized mice. Our study demonstrated a dose-dependent therapeutic effect in vivo . Unwanted off-target effects were not observed at the whole-genome sequencing level. Our study provides strong support for the further development of this effective therapeutic drug to treat RHO -T17M-associated adRP, also offers a generalizable framework for developing gene-editing medicine. Furthermore, our success in restoring the vision loss in the suffering RHO humanized mice verifies the feasibility of allele-specific CRISPR/Cas9-based medicines for other autosomal dominant inherited retinal dystrophies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RhodopsinRetinitis PigmentosaMiceAnimalsHumansAllelesHEK293 CellsRetinaVision Disorders

Stichwörter der Autor:innen

CRISPR/Cas9adeno-associated virusgeneticsgenomicshumanhumanzied miceiPSCsmousenonhuman primateretinitis pigmentosarhodopsin

Substanzen

Rhodopsin

Autor:innen und Institutionen

  • Department of Ophthalmology, Third Hospital, Peking University, Beijing, China.
  • Beijing Key Laboratory of Restoration of Damaged Ocular Nerve, Peking University Third Hospital,, Beijing, China.
  • Beijing Chinagene Co., LTD, Beijing, China.
  • Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China.

ORCID-Profile: Xiaozhen Liu, Liping Yang

Förderung

  • the National Natural Science Foundation of China
  • the Beijing Natural Science Foundation of China

Zitieren

APA

Liu, X., Qiao, J., Jia, R., Zhang, F., Meng, X., Li, Y., & Yang, L. (2023). Allele-specific gene-editing approach for vision loss restoration in RHO-associated retinitis pigmentosa. eLife. https://doi.org/10.7554/elife.84065

Vancouver

Liu X, Qiao J, Jia R, Zhang F, Meng X, Li Y, et al. Allele-specific gene-editing approach for vision loss restoration in RHO-associated retinitis pigmentosa. eLife. 2023. doi:10.7554/elife.84065

BibTeX
@article{Liu2023,
  author = {Liu, Xiaozhen and Qiao, Jing and Jia, Ruixuan and Zhang, Fan and Meng, Xiang and Li, Yang and Yang, Liping},
  title = {Allele-specific gene-editing approach for vision loss restoration in RHO-associated retinitis pigmentosa},
  journal = {eLife},
  year = {2023},
  doi = {10.7554/elife.84065}
}
Kostenlos starten →